Phase 2
Completed N=131
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
Cystitis, Interstitial · Painful Bladder Syndrome
Source: ClinicalTrials.gov NCT02411110 ↗
Enrolled (actual)
131
Serious AEs
1.8%
Results posted
Jan 2018
Primary outcomePrimary: Change From Baseline in Daily Average Bladder Pain to Treatment 1 Week 4 Follow-up — -1.2; -1.5 score on a scale — p=0.505
Summary
This is a safety and efficacy study of LiRIS® in females with interstitial cystitis/bladder pain syndrome.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Daily Average Bladder Pain to Treatment 1 Week 4 Follow-up |
-1.2; -1.5 | 0.505 |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of interstitial cystitis or bladder pain syndrome
Exclusion Criteria
- Diagnosis of interstitial cystitis with Hunner's lesions/ulcers
- Previous treatment with LiRIS®
Data sourced from ClinicalTrials.gov (NCT02411110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.